Clinical Trial

3Daughters Successfully Closes Over $2 million in First Tranche of Seed Financing Round

Funding will accelerate development of a Novel IUD for contraception for IND filing in 2024MANSFIELD, Mass., Jan. 22, 2024 (GLOBE…

2 months ago

ReiThera Srl, The Ragon Institute and IAVI Announce Collaboration to Advance Highly Networked T Cell HIV Vaccine Candidate Towards Phase I Clinical Evaluation

 Novel HIV vaccine candidate based on Gorilla adenoviral vector (GRAd-HIV) funded by the Bill & Melinda Gates Foundation to alleviate…

2 months ago

Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.

SAN DIEGO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic…

2 months ago

Angle PLC Announces Potential Utility in Precision Oncology

REVIEW PAPER ON MOLECULAR ANALYSIS OF PARSORTIX CTC HARVEST HIGHLIGHTS POTENTIAL UTILITY IN PRECISION ONCOLOGYPaper published in the journal "Current…

2 months ago

Defence Financing

Vancouver, British Columbia--(Newsfile Corp. - January 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the…

2 months ago

Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

- 10,000-subject Phase 2b study would evaluate Vaxart’s next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine…

2 months ago

ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024

MADRID, Spain and BOSTON, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical…

2 months ago

MangoRx’s Brand and Products to be Featured by Barstool Sports in Week of Programming Around the Biggest Sports Event of the Year on February 11

"King of the Internet" Dave Portnoy's Uber-Popular Sports Media Company to Spotlight FDA-Approved Oral Testosterone Replacement ‘Prime’ by MangoRx, Powered…

2 months ago

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates…

2 months ago

United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

REVASCOR Increases Size of Left Heart Chamber and Improves Surgical Outcomes in Children with Hypoplastic Left Heart Syndrome: Results Published…

2 months ago